Departed
Lawrence D. McGovern
Chief Financial Officer
HERITAGE COMMERCE CORP
Mr. McGovern will depart on or about February 15, 2025
Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 3101–3150 of 18397
Mr. McGovern will depart on or about February 15, 2025
the appointment of Thomas A. Sa to serve on an interim role as Chief Financial Officer effective November 18, 2024
On November 11, 2024, the board of directors of the Company (the " Board ") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.
On November 11, 2024, Mark K. Oki was terminated as Chief Financial Officer of the Company.
On the same day, Boriss Aleksandrov was appointed as the sole Officer and Director of the Company, assuming all roles, including, but not limited to, CEO, CFO, President, Secretary, Treasurer, and sole Director.
Mr. Clint C. Freeland informed The Mosaic Company ("Mosaic") of his intention to retire from Mosaic in 2025. In connection with his retirement, Mr. Freeland will resign as the Executive Vice President and Chief Financial Officer effective December 31, 2024
Mosaic announced that effective November 18, 2024, its Board of Directors ("Board") appointed Mr. Luciano Siani Pires to the position of Executive Vice President and Chief Financial Officer - Designate.
On November 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Julie Eastland as Chief Executive Officer, President and a Class I director of the Company with an initial term scheduled to expire at the Company’s 2027 Annual Meeting of Stockholders, in each case effective November 13, 2024 (the “Transition Date”).
Also on November 12, 2024, Kimberly Blackwell, M.D., resigned as Chief Executive Officer, a member of the Board and from all other positions held with the Company and its affiliates, effective on the Transition Date.
Steven G. Burdette, 63, Havertys’ president will become president and chief executive officer and a member of the Board.
The Board of Directors (the “Board”) of Jack in the Box Inc. (the “Company”) appointed Mr. Lance Tucker to serve as the Company’s Executive Vice President, Chief Financial Officer (“CFO”), effective upon his first day of employment on January 13, 2025.
Pete Beckmann, Senior Vice President, FP&A of the Company, as the Company’s next Executive Vice President and Chief Financial Officer.
Mr. Jackson will succeed Dave Rush as President & Chief Executive Officer.
Mr. Rush served as President & Chief Executive Officer since November 2022 and is retiring after 25 years of dedicated service to the Company, effective November 6, 2024.
the Board of Directors has appointed Matthew Pauli as Senior Vice President and Chief Financial Officer effective November 13, 2024.
the Company will continue to employ Dennis Bowe, who served as the Company’s Chief Financial Officer from September 1, 2022 through November 12, 2024, through February 7, 2025 to assist in the transition in an advisory role.
appointed Alex J. Panda as the Company’s Executive Vice President, Secretary, Treasurer and Chief Financial Officer, effective as of June 1, 2025
announced the planned transition and departure of John P. Zimmer as the Company’s Executive Vice President, Secretary, Treasurer and Chief Financial Officer, which departure will be effective as of May 31, 2025
On November 11, 2024, Chipotle Mexican Grill, Inc. (“Chipotle”) announced that its Board of Directors has appointed Scott Boatwright, age 52, as Chief Executive Officer and as a member of the Board of Directors of Chipotle, effective immediately.
On November 8, 2024, Dr Hj Mazlan Hj Ahmad submitted a letter of resignation as Chief Executive Officer and as a member of the Board of Directors (the “Board”) of QMIS TBS Capital Group Corp., a Delaware corporation (the “Company”), effective immediately.
In connection with Mr. Krawtschuk’s appoinment, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, Steven Ratoff, stepped down from serving in such capacities on the Effective Date and will remain as a director on the Company’s board of directors.
On November 8, 2024, the Board of Directors (the “Board”) of Eagle Pharmaceuticals, Inc. (the “Company”) appointed Christopher Krawtschuk to serve as the Company’s Chief Financial Officer, and designated Mr. Krawtschuk as its principal financial officer and principal accounting officer, each effective November 11, 2024
Effective as of November 5, 2024, due to the illness of the Chief Executive Officer, Charles Wert, Oanh Truong was appointed as interim Chief Executive Officer of Coliseum Acquisition Corp.
due to the illness of the Chief Executive Officer, Charles Wert
On November 8, 2024, iSpecimen Inc. (the “Company”) and Tracy Curley mutually agreed to end Ms. Curley’s employment as Chief Executive Officer, Chief Financial Officer and Treasurer of the Company.
On November 7, 2024, Joseph E. Sutaris notified Community Financial System, Inc. (the “Company”) of his intention to retire, effective in or around the third quarter of 2025, from his position as the Executive Vice President (“EVP”) and Chief Financial Officer of the Company
Ms. Cathy W. Liles, age 59, has been appointed to the position of Senior Vice President and Chief Financial Officer of the Company and Executive Vice President and Chief Financial Officer of The Old Point National Bank of Phoebus (the “Bank”) effective as of November 6, 2024.
the resignation of Mr. William H. Craig as Chief Financial Officer and Treasurer of the Company
the Company’s board of directors (“Board”) appointed George A. Makris, Jr. (age 68) as chairman and chief executive officer of the Company, effective January 1, 2025
Robert A. Fehlman (age 60), the chief executive officer of Simmons First National Corporation (“Company”), provided the Company notice of his decision to resign from his position, effective as of the end of the day December 31, 2024, to focus on personal interests and family medical issues.
Appointment of Officers Immediately upon consummation of the Transaction, the executive officers of the Company are: (i) Robbert Rietbroek, as Chief Executive Officer; (ii) David Hass, as Chief Financial Officer; (iii) Robert Austin, as Chief Operating Officer, (iv) Jason Ausher, as Chief Accounting Officer; (v) Marni Morgan Poe, as General Counsel & Corporate Secretary; and (vi) Hih Song Kim, as Chief Administrative Officer & Assistant Corporate Secretary.
Appointment of Officers Immediately upon consummation of the Transaction, the executive officers of the Company are: (i) Robbert Rietbroek, as Chief Executive Officer; (ii) David Hass, as Chief Financial Officer; (iii) Robert Austin, as Chief Operating Officer, (iv) Jason Ausher, as Chief Accounting Officer; (v) Marni Morgan Poe, as General Counsel & Corporate Secretary; and (vi) Hih Song Kim, as Chief Administrative Officer & Assistant Corporate Secretary.
On November 11, 2024, Altimmune, Inc. (the “Company”) issued a press release announcing the decision of the Company’s Board of Directors (the “Board”) to appoint Mr. Gregory Weaver as the Company’s Chief Financial Officer (“CFO”), effective November 11, 2024.
The board of directors of the Company has appointed Constance B. Moore to serve as the Company's Interim President and Chief Executive Officer effective November 11, 2024.
On November 11, 2024, Healthcare Realty Trust Incorporated (the "Company") and Todd J. Meredith determined that Mr. Meredith would depart from his position as President and Chief Executive Officer of the Company, effective November 11, 2024.
the Board approved the appointment of Scott R. Cutler as President and Chief Executive Officer, effective as of January 6, 2025
Jon Kessler, President & Chief Executive Officer of the Company and a member of the Board of Directors (the “Board”), will retire from his employment with the Company, effective January 6, 2025
Herman Cueto, who is departing from his role at the Company.
appointed Lawrence Lin as its Executive Vice President and Chief Financial Officer, effective as of Effective Time
Mr. Dellal will resign from his role as of the Effective Date.
On November 11, 2024 , the Board of Directors of Two Harbors Investment Corp. (the “Company”) approved the appointment of Travis Swenson as Chief Financial Officer of the Company, with an effective date of May 5, 2025
On November 6, 2024 (the “Effective Date”), the Company entered into an employment agreement with Mr. Waqas Nakhwa in connection with his appointment as Chief Executive Officer, President, Chief Financial Officer, Treasurer, Secretary, and as Chairman of the Company’s Board of Directors
Mr. Kevin Zaccardi resigned as the Interim-Chief Financial Officer of Starco Brands, Inc. (the “Company”), effective November 8, 2024, to pursue another opportunity.
On November 8, 2024, the Board unanimously approved the appointment of Mr. Sklar, the Company’s current Chief Executive Officer and President, and member of the Board, to the position of Interim-Chief Financial Officer and Treasurer, effective November 8, 2024.
the Company appointed Peter F. Longo as President and CEO of the Company.
On November 6, 2024, the Company announced the engagement of James Richardson as Chief Financial Officer of the Company, effective January 1, 2025.
On November 5, 2024, our board of directors appointed Annalisa Bloodworth, 46, as our next President and Chief Executive Officer.
On November 7, 2024, the Board approved the appointment of Douglas Francis, age 47, to serve as Chief Executive Officer of the Company, effective as of November 7, 2024.
On November 7, 2024, the Board approved the appointment of Ms. Echard as the Company’s permanent Chief Financial Officer.
his appointment as Executive Vice President and Chief Financial Officer is now effective November 8, 2024.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.